

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended): A method of detecting and localizing ~~malignant tumours~~ CCK-B receptor expressing tumours selected from the group consisting of Small Cell Lung Carcinoma, Medullary Thyroid Carcinoma, Breast Carcinoma, Stromal Ovarian Carcinoma and Muscle Sarcoma or their metastases in tissues, which in healthy condition do not contain substantial quantities of CCK-receptors, in the body of a human being, which comprises (i) administering to said human being a composition comprising, in a quantity sufficient for external imaging, a peptide derived from a compound of the general formula

$H - (Xaa)_n - (Xbb)_m - Tyr - Xcc - Gly - Trp - Xdd - Asp - Phe - R_2$  (I) (SEQ ID NO:27)  
or an acid amide thereof, formed between a free  $NH_2$ -group of an amino acid moiety and  $R_1COOH$ , wherein

$R_1$  is a  $(C_1-C_3)$ alkanoyl group, an arylcarbonyl group, or an aryl- $(C_1-C_3)$ alkanoyl group; or a lactam thereof, formed between a free  $NH_2$  group of an amino acid moiety and a free  $CO_2H$  group of another amino acid moiety; or a conjugate thereof with avidin or biotin; wherein:

$(Xaa)_n$  stands for 0 to 25 amino acid moieties which are equal or different and are selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg, Tyr, Trp, Val and Phe;

$m = 0$  or  $1$ ;

$Xbb$  is Asp, Dpr, Glu or Pyr; with the proviso that  $Xbb$  can only be Pyr when  $n = 0$ ;

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and

R<sub>2</sub> is a hydroxy group, an acetoxy group or an amino group;

wherein one or more of the amino acids of said peptide can be in the D-configuration and wherein said peptide may comprise pseudo peptide bonds;

said peptide being labelled with (a) a radioactive metal isotope selected from the group consisting of <sup>99m</sup>Tc, <sup>203</sup>Pb, <sup>67</sup>Ga, <sup>68</sup>Ga, <sup>72</sup>As, <sup>111</sup>In, <sup>113m</sup>In, <sup>97</sup>Ru, <sup>62</sup>Cu, <sup>64</sup>Cu, <sup>52</sup>Fe, <sup>52m</sup>Mn and <sup>51</sup>Cr, or (b) with a paramagnetic metal atom selected from the group consisting of Cr, Mn, Fe, Co, Ni, Cu, Pr, Nd, Sm, Yb, Gd, Tb, Dy, Ho and Er, or (c) with a radioactive halogen isotope, selected from <sup>123</sup>I, <sup>124</sup>I, <sup>125</sup>I, <sup>131</sup>I, <sup>75</sup>Br, <sup>76</sup>Br, <sup>77</sup>Br and <sup>82</sup>Br, and thereupon (ii) subjecting said human being to external imaging, by radioactive scanning or by magnetic resonance imaging, to determine the targeted sites in the body of said human being in relation to the background activity, in order to allow detection and localization of said CCK-B receptor expressing tumours in the body.

2. (Currently Amended): A method of detecting and localizing ~~malignant tumours~~ CCK-B receptor expressing tumours selected from the group consisting of Small Cell Lung Carcinoma, Medullary Thyroid Carcinoma, Breast Carcinoma, Stromal Ovarian Carcinoma and Muscle Sarcoma or their metastases, which in healthy condition do not contain substantial quantities of CCK-receptors, in the body of a human being, which comprises (i) administering to said human being a composition comprising, in a general quantity sufficient for detection by a gamma detecting probe, a peptide derived from a compound of the general formula  
H - (Xaa)<sub>n</sub> - (Xbb)<sub>m</sub> - Tyr - Xcc - Gly - Trp - Xdd - Asp - Phe - R<sub>2</sub> (I) (SEQ ID NO:27)  
or an acid amide thereof, formed between a free NH<sub>2</sub>-group of an amino acid moiety and R<sub>1</sub>COOH;

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

or a lactam thereof, formed between a free  $\text{NH}_2$  group of an amino acid moiety and a free  $\text{CO}_2\text{H}$  group of another amino acid moiety;

or a conjugate thereof with avidin or biotin; wherein,

$\text{R}_1$  is a  $(\text{C}_1\text{-C}_3)$ alkanoyl group, an arylcarbonyl group, or an aryl- $(\text{C}_1\text{-C}_3)$ alkanoyl group;

$(\text{Xaa})_n$  stands for 0 to 25 amino acid moieties which are equal or different and are selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg, Tyr, Trp, Val and Phe;

$m=0$  or 1;

Xbb is Asp, Dpr, Glu or Pyr; with the proviso that Xbb can only be Pyr when  $n=0$ ;

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and

$\text{R}_2$  is a hydroxy group, an acetoxy group or an amino group;

wherein one or more of the amino acids of said peptide can be in the D-configuration and

wherein said peptide may comprise pseudo peptide bonds;

said peptide being labeled with  $^{161}\text{Tb}$ ,  $^{123}\text{I}$ ,  $^{125}\text{I}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{72}\text{As}$ ,  $^{111}\text{In}$ ,  $^{113\text{m}}\text{In}$ ,  $^{62}\text{Cu}$ ,  $^{64}\text{Cu}$ ,  $^{52}\text{Fe}$ ,  $^{52\text{m}}\text{Mn}$  or  $^{51}\text{Cr}$  and thereupon (ii), after allowing the active substance to be bound and taken up in said CCK-B receptor expressing tumours and after blood clearance of radioactivity, subjecting said human being to a radioimmunodetection technique in the relevant area of the body of said human being, by using a gamma detecting probe.

3. (Currently Amended): A method for the therapeutic treatment of ~~malignant tumours~~  
CCK-B receptor expressing tumours selected from the group consisting of Small Cell Lung Carcinoma, Medullary Thyroid Carcinoma, Breast Carcinoma, Stromal Ovarian Carcinoma and

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

Muscle Sarcoma ~~that express CCK-receptor~~ or their metastases in tissues, which in healthy condition do not contain substantial quantities of CCK-receptors, in the body of a human being, which comprises administering to said human being a composition comprising, in a quantity effective for combating or controlling CCK-B receptor expressing tumours, a peptide derived from a compound of the general formula

H - (Xaa)<sub>n</sub> - (Xbb)<sub>m</sub> - Tyr - Xcc - Gly - Trp - Xdd - Asp - Phe - R<sub>2</sub> (I) (SEQ ID NO:27)

or an acid amide thereof, formed between a free NH<sub>2</sub>-group of an amino acid moiety and R<sub>1</sub>COOH;

or a lactam thereof, formed between a free NH<sub>2</sub> group of an amino acid moiety and a free CO<sub>2</sub>H group of another amino acid moiety;

or a conjugate thereof with avidin or biotin; wherein

R<sub>1</sub> is a C<sub>1</sub>-C<sub>3</sub>alkanoyl group, an arylcarbonyl group, or an aryl-(C<sub>1</sub>-C<sub>3</sub>)alkanoyl group;

(Xaa)<sub>n</sub> stands for 0 to 25 amino acid moieties which are equal or different and are selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg, Tyr, Trp, Val and Phe;

m = 0 or 1;

Xbb is Asp, Dpr, Glu or Pyr; with the proviso that Xbb can only be Pyr when n = 0;

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and

R<sub>2</sub> is a hydroxy group, an acetoxy group or an amino group;

said peptide being labeled with an isotope selected from the group consisting of <sup>186</sup>Re, <sup>188</sup>Re, <sup>77</sup>As, <sup>90</sup>Y, <sup>67</sup>Cu, <sup>169</sup>Er, <sup>121</sup>Sn, <sup>127</sup>Te, <sup>142</sup>Pr, <sup>143</sup>Pr, <sup>198</sup>Au, <sup>199</sup>Au, <sup>161</sup>Tb, <sup>109</sup>Pd, <sup>165</sup>Dy, <sup>149</sup>Pm, <sup>151</sup>Pm, <sup>153</sup>Sm, <sup>157</sup>Gd, <sup>159</sup>Gd, <sup>166</sup>Ho, <sup>172</sup>Tm, <sup>169</sup>Yb, <sup>175</sup>Yb, <sup>177</sup>Lu, <sup>105</sup>Rh, <sup>111</sup>Ag, <sup>125</sup>I, <sup>131</sup>I, and <sup>82</sup>Br.

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

4. (Cancelled):

5. (Cancelled):


6. (Previously Presented): The method of claim 1, 2 or 3, wherein said peptide is selected from the group consisting of H-DTyr-Gly-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:11), H-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:2), H-Asp-Tyr-Nle-Gly-Trp-Nle-Asp--Phe-NH<sub>2</sub> (SEQ ID NO:3), H-DAsp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO :4), H-DAsp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:5) and H-Dpr-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:6).

7. (Previously Presented): The method of claim 1, wherein said peptide is labeled with a radioactive halogen isotope selected from the group consisting of <sup>123</sup>I, <sup>124</sup>I, <sup>125</sup>I, <sup>131</sup>I, <sup>75</sup>Br, <sup>76</sup>Br, <sup>77</sup>Br and <sup>82</sup>Br, said radioactive halogen isotope being attached to a Tyr or Trp moiety of the peptide, or to the aryl group of substituent R<sub>1</sub>.

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

8. (Previously Presented): The method of claim 1, wherein said radioactive metal isotope or said paramagnetic metal atom is attached to the peptide by means of a chelating group chelating said isotope or atom, which chelating group is bound by an amide bond or through a spacing group to the peptide molecule.


9. (Previously Presented): The method of claim 8, wherein said composition comprises a peptide labeled with a metal atom, chelated by an  $N_tS_{(4-t)}$  tetradentate chelating agent, wherein  $t=2-4$ , or by a chelating group comprising ethylene diamine tetra-acetic acid (EDTA), diethylene triamine penta-acetic acid (DTPA), cyclohexyl 1,2-diamine tetra-acetic acid (CDTA), ethyleneglycol-0,0'-bis(2-aminoethyl)-N,N,N',N'-tetra-acetic acid (EGTA), N,N-bis(hydroxybenzyl)-ethylenediamine-N,N'-diacetic acid (HBED), triethylene tetramine hexa-acetic acid (TTHA), 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetra-acetic acid (DOTA), hydroxyethyldiamine triacetic acid (HEDTA), 1,4,8,11-tetra-azacyclotetradecane-N,N',N'',N'''-tetra-acetic acid (TETA), or a compound of the general formula




wherein S is sulfur, R is a branched or non-branched, optionally substituted hydrocarbonyl radical, which may be interrupted by one or more hetero-atoms selected from N, O and S and/or by one or more NH groups, and Q is a group which is capable of reacting with an amino group of the peptide and which is selected from the group consisting of carbonyl, carbimidoyl, N-(C<sub>1</sub>-

Application Serial No. 10/626,229  
 Third Preliminary Amendment  
 Inventor(s) Name: Jean-Claude Reubi  
 Attorney Docket No.: 717816.23

C<sub>6</sub>)alkylcarbimidoyl, N-hydroxycarbimidoyl and N-(C<sub>1</sub>-C<sub>6</sub>)alkoxycarbimidoyl; and  
 wherein said optionally present spacing group is a biotinyl moiety or has the general formula



wherein R<sub>3</sub> is a C<sub>1</sub>-C<sub>10</sub> alkylene group, a C<sub>1</sub>-C<sub>10</sub> alkylidene group or a C<sub>2</sub>-C<sub>10</sub> alkenylene group,  
 and X is a thiocarbonyl group or a group of the general formula



wherein p is 1-5.

10. (Cancelled).

11. (Cancelled).

12. (Currently Amended): A pharmaceutical composition comprising, in addition to a pharmaceutically acceptable carrier material and, if desired, at least one pharmaceutically acceptable adjuvant, as the active substance, in a quantity sufficient for external imaging, or detection by a gamma detecting probe or for combating or controlling tumours, CCK-B receptor

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

expressing tumours selected from the group consisting of Small Cell Lung Carcinoma,

Medullary Thyroid Carcinoma, Breast Carcinoma, Stromal Ovarian Carcinoma and Muscle

Sarcoma Medullary Thyroid Carcinoma, a peptide of the general formula

H - (Xaa)<sub>n</sub> - (Xbb)<sub>m</sub> - Tyr - Xcc - Gly - Trp - Xdd - Asp - Phe - R<sub>2</sub> (I) (SEQ ID NO:27)

formed between a free NH<sub>2</sub>-group of an amino acid moiety and R<sub>1</sub>COOH;

or a lactam thereof, formed between a free NH<sub>2</sub> group of an amino acid moiety and a free CO<sub>2</sub>H group of another amino acid moiety;

or a conjugate thereof with avidin or biotin; wherein

R<sub>1</sub> is a (C<sub>1</sub>-C<sub>3</sub>)alkanoyl group, an arylcarbonyl group, or an aryl-(C<sub>1</sub>-C<sub>3</sub>)alkanoyl group;

(Xaa)<sub>n</sub> stands for 0 to 25 amino acid moieties which are equal or different and are selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg, Tyr, Trp, Val and Phe;

m = 0 or 1;

Xbb is Asp, Dpr, Glu or Pyr; with the proviso that Xbb can only be Pyr when n = 0;

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and

R<sub>2</sub> is a hydroxy group, an acetoxy group or an amino group;

wherein one or more of the amino acids of said peptide can be in the D-configuration and

wherein said peptide may comprise pseudo peptide bonds;

said peptide being labelled with (a) a radioactive metal isotope selected from the group

consisting of <sup>99m</sup>Tc, <sup>203</sup>Pb, <sup>66</sup>Ga, <sup>67</sup>Ga, <sup>68</sup>Ga, <sup>72</sup>As, <sup>111</sup>In, <sup>113m</sup>In, <sup>114m</sup>In, <sup>97</sup>Ru, <sup>62</sup>Cu, <sup>64</sup>Cu, <sup>52</sup>Fe,

<sup>52m</sup>Mn, <sup>51</sup>Cr, <sup>186</sup>Re, <sup>188</sup>Re, <sup>77</sup>As, <sup>90</sup>Y, <sup>67</sup>Cu, <sup>169</sup>Er, <sup>117m</sup>Sn, <sup>121</sup>Sn, <sup>127</sup>Te, <sup>142</sup>Pr, <sup>143</sup>Pr, <sup>198</sup>Au, <sup>199</sup>Au,

<sup>149</sup>Tb, <sup>161</sup>Tb, <sup>109</sup>Pd, <sup>165</sup>Dy, <sup>149</sup>Pm, <sup>151</sup>Pm, <sup>153</sup>Sm, <sup>157</sup>Gd, <sup>159</sup>Gd, <sup>166</sup>Ho, <sup>172</sup>Tm, <sup>169</sup>Yb, <sup>175</sup>Yb, <sup>177</sup>Lu,



Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

$^{105}\text{Rh}$  and  $^{111}\text{Ag}$ , or (b) with a paramagnetic metal atom selected from the group consisting of Cr, Mn, Fe, Co, Ni, Cu, Pr, Nd, Sm, Yb, Gd, Tb, Dy, Ho and Er, or (c) with a radioactive halogen isotope, selected from the group consisting of  $^{123}\text{I}$ ,  $^{124}\text{I}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{75}\text{Br}$ ,  $^{76}\text{Br}$ ,  $^{77}\text{Br}$  and  $^{82}\text{Br}$ .

13. (Previously Presented): The composition of claim 12, wherein said active substance is a derivatized peptide selected from the group consisting of DTPA-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:19), DTPA-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:20), DTPA-DAsp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:21), DTPA-DAsp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub> (SEQ ID NO :22) and Dpr( $\beta$ -DTPA)-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:23), wherein said derivatized peptide is labeled with a metal isotope or atom attached to the peptide by means of a chelating group chelating said isotope or atom, which chelating group is bound by an amide bond or through a spacing group to the peptide molecule.

14. (Previously Presented): The composition of claim 13, wherein said derivatized peptide is DTPA-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:20) or DTPA-DAsp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:21).

15 (Cancelled).

16 (Cancelled).

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

17. (Cancelled).

18 (Cancelled).

19. (Cancelled).

20. (Cancelled).

21 (Cancelled).

22. (Cancelled).

23. (Currently Amended): The method of ~~claim 2 wherein~~ claim 2, wherein said  $^{161}\text{Tb}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{72}\text{As}$ ,  $^{111}\text{In}$ ,  $^{113\text{m}}\text{In}$ ,  $^{62}\text{Cu}$ ,  $^{64}\text{Cu}$ ,  $^{52}\text{Fe}$ ,  $^{52\text{m}}\text{Mn}$  or  $^{51}\text{Cr}$  is attached to the peptide by means of a chelating group chelating said  $^{161}\text{Tb}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{72}\text{As}$ ,  $^{111}\text{In}$ ,  $^{113\text{m}}\text{In}$ ,  $^{62}\text{Cu}$ ,  $^{64}\text{Cu}$ ,  $^{52}\text{Fe}$ ,  $^{52\text{m}}\text{Mn}$  or  $^{51}\text{Cr}$  which chelating group is bound by an amide bond or through a spacing group to the peptide molecule.

24 (Currently Amended): The method of ~~claim 3 wherein~~ claim 3, wherein said isotope is attached to the peptide by means of a chelating group chelating said isotope, which chelating group is bound by an amide bond or through a spacing group to the peptide molecule.

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

25 (Previously Presented): A pharmaceutical composition comprising, in addition to a pharmaceutically acceptable carrier material and, optionally, at least one pharmaceutically acceptable adjuvant, as the active substance, in a quantity sufficient for detecting and localizing malignant tumours, a peptide selected from the group consisting of [ $^{125}\text{I}$ -D-Tyr]-Gly-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO: 13) and D-Tyr-Gly-Asp-[ $^{125}\text{I}$ -Tyr]-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ IDNO:14).

26. (Cancelled):

27. (Currently Amended): A labelled peptide of the general formula

H-(Xaa)<sub>n</sub>- (Xbb)<sub>m</sub>- Tyr - Xcc - Gly - Trp - Xdd - Asp - Phe - R<sub>2</sub> (I) (SEQ ID NO:27)  
or an acid amide thereof, formed between a free NH<sub>2</sub>-group of an amino acid moiety and  
R<sub>1</sub>COOH, wherein

R<sub>1</sub> is a (C<sub>1</sub>-C<sub>3</sub>)alkanoyl group, an arylcarbonyl group, or an aryl-(C<sub>1</sub>-C<sub>3</sub>)alkanoyl group;  
or a lactam thereof, formed between a free NH<sub>2</sub> group of an amino acid moiety and a free CO<sub>2</sub>H  
group of another amino acid moiety;  
or a conjugate thereof with avidin or biotin;  
wherein:

(Xaa)<sub>n</sub> stands for 0 to 25 amino acid moieties which are equal or different and are  
selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg,  
Tyr, Trp, Val and Phe;

m = 0 or 1;

Xbb is Asp, Dpr, Glu or Pyr; with the proviso that Xbb can only be Pyr when n = 0;

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and

R<sub>2</sub> is a hydroxy group, an acetoxy group or an amino group;

wherein one or more of the amino acids of said peptide can be in the D-configuration and

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

wherein said peptide may comprise pseudo peptide bonds;

said peptide being labelled with (a) a radioactive metal isotope selected from the group

consisting of  $^{99m}\text{Tc}$ ,  $^{203}\text{Pb}$ ,  $^{66}\text{Ga}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{72}\text{As}$ ,  $^{111}\text{In}$ ,  $^{113m}\text{In}$ ,  $^{114m}\text{In}$ ,  $^{97}\text{Ru}$ ,  $^{62}\text{Cu}$ ,  $^{64}\text{Cu}$ ,  $^{52}\text{Fe}$ ,

$^{52m}\text{Mn}$ ,  $^{51}\text{Cr}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{77}\text{As}$ ,  $^{90}\text{Y}$ ,  $^{67}\text{Cu}$ ,  $^{169}\text{Er}$ ,  $^{117m}\text{Sn}$ ,  $^{121}\text{Sn}$ ,  $^{127}\text{Te}$ ,  $^{142}\text{Pr}$ ,  $^{143}\text{Pr}$ ,  $^{198}\text{Au}$ ,  $^{199}\text{Au}$ ,

$^{149}\text{Tb}$ ,  $^{161}\text{Tb}$ ,  $^{109}\text{Pd}$ ,  $^{165}\text{Dy}$ ,  $^{149}\text{Pm}$ ,  $^{151}\text{Pm}$ ,  $^{153}\text{Sm}$ ,  $^{157}\text{Gd}$ ,  $^{159}\text{Gd}$ ,  $^{166}\text{Ho}$ ,  $^{172}\text{Tm}$ ,  $^{169}\text{Yb}$ ,  $^{175}\text{Yb}$ ,  $^{177}\text{Lu}$ ,

$^{105}\text{Rh}$  and  $^{111}\text{Ag}$ , or (b) with a paramagnetic metal atom selected from the group consisting of Cr,

Mn, Fe, Co, Ni, Cu, Pr, Nd, Sm, Yb, Gd, Tb, Dy, Ho and Er, or (c) with a radioactive halogen

isotope, selected from  $^{123}\text{I}$ ,  $^{124}\text{I}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{75}\text{Br}$ ,  $^{76}\text{Br}$ ,  $^{77}\text{Br}$  and  $^{82}\text{Br}$ , wherein ~~The labelled peptide~~

~~of claim 26 wherein~~ said metal isotope or said metal atom is attached to the peptide by means of

a chelating group chelating said metal isotope or said metal atom, which chelating group is

bound by an amide bond or through a spacing group to the peptide molecule.

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

28 (Currently Amended): A labelled peptide of the general formula

H-(Xaa)<sub>n</sub>- (Xbb)<sub>m</sub>- Tyr - Xcc - Gly - Trp - Xdd - Asp - Phe - R<sub>2</sub> (I) (SEQ ID NO:27)

or an acid amide thereof, formed between a free NH<sub>2</sub>-group of an amino acid moiety and

R<sub>1</sub>COOH, wherein

R<sub>1</sub> is a (C<sub>1</sub>-C<sub>3</sub>)alkanoyl group, an arylcarbonyl group, or an aryl-(C<sub>1</sub>-C<sub>3</sub>)alkanoyl group;  
or a lactam thereof, formed between a free NH<sub>2</sub> group of an amino acid moiety and a free CO<sub>2</sub>H  
group of another amino acid moiety;

or a conjugate thereof with avidin or biotin;

wherein:

(Xaa)<sub>n</sub> stands for 0 to 25 amino acid moieties which are equal or different and are  
selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg,  
Tyr, Trp, Val and Phe;

m = 0 or 1;

Xbb is Asp, Dpr, Glu or Pyr; with the proviso that Xbb can only be Pyr when n = 0;

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and


R<sub>2</sub> is a hydroxy group, an acetoxy group or an amino group;

wherein one or more of the amino acids of said peptide can be in the D-configuration and  
wherein said peptide may comprise pseudo peptide bonds;

said peptide being labelled with (a) a radioactive metal isotope selected from the group  
consisting of <sup>99m</sup>Tc, <sup>203</sup>Pb, <sup>66</sup>Ga, <sup>67</sup>Ga, <sup>68</sup>Ga, <sup>72</sup>As, <sup>111</sup>In, <sup>113m</sup>In, <sup>114m</sup>In, <sup>97</sup>Ru, <sup>62</sup>Cu, <sup>64</sup>Cu, <sup>52</sup>Fe,  
<sup>52m</sup>Mn, <sup>51</sup>Cr, <sup>186</sup>Re, <sup>188</sup>Re, <sup>77</sup>As, <sup>90</sup>Y, <sup>67</sup>Cu, <sup>169</sup>Er, <sup>117m</sup>Sn, <sup>121</sup>Sn, <sup>127</sup>Te, <sup>142</sup>Pr, <sup>143</sup>Pr, <sup>198</sup>Au, <sup>199</sup>Au,  
<sup>149</sup>Tb, <sup>161</sup>Tb, <sup>109</sup>Pd, <sup>165</sup>Dy, <sup>149</sup>Pm, <sup>151</sup>Pm, <sup>153</sup>Sm, <sup>157</sup>Gd, <sup>159</sup>Gd, <sup>166</sup>Ho, <sup>172</sup>Tm, <sup>169</sup>Yb, <sup>175</sup>Yb, <sup>177</sup>Lu,  
<sup>105</sup>Rh and <sup>111</sup>Ag, or (b) with a paramagnetic metal atom selected from the group consisting of Cr,  
Mn, Fe, Co, Ni, Cu, Pr, Nd, Sm, Yb, Gd, Tb, Dy, Ho and Er, or (c) with a radioactive halogen  
isotope, selected from <sup>123</sup>I, <sup>124</sup>I, <sup>125</sup>I, <sup>131</sup>I, <sup>75</sup>Br, <sup>76</sup>Br, <sup>77</sup>Br and <sup>82</sup>Br, wherein The labelled peptide

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23


of claim 26 wherein said metal isotope or said metal atom is attached to the peptide by means of a chelating group chelating said metal isotope or said metal atom, wherein said chelating group is a tetradentate chelating agent or comprises ethylene diamine tetra-acetic acid (EDTA), diethylene triamine penta-acetic acid (DTPA), cyclohexyl 1,2-diamine tetra-acetic acid (CDTA), ethyleneglycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), N,N-bis(hydroxybenzyl)-ethylenediamine-N,N'-diacetic acid (HBED), triethylene tetramine hexa-acetic acid (TTHA), 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetra-acetic acid (DOTA), hydroxyethyldiamine triacetic acid (HEDTA), 1,4,8,11-tetra-azacyclo-tetradecane-N,N',N'',N'''-tetra-acetic acid (TETA), substituted EDTA, or from a compound of the general formula




wherein S is sulfur, R is a branched or non-branched, optionally substituted hydrocarbyl radical, which may be interrupted by one or more hetero-atoms selected from N, O and S and/or by one or more NH groups, and Q is a peptide and which is selected from the group consisting of carbonyl, carbimidoyl, -(C<sub>1</sub>-C<sub>6</sub>)alkylcarbimidoyl, N-hydroxycarbimidoyl and N-(C<sub>1</sub>-C<sub>6</sub>)alkoxycarbimidoyl; and wherein said optionally present spacing group is a biotinyl moiety or

Application Serial No. 10/626,229  
 Third Preliminary Amendment  
 Inventor(s) Name: Jean-Claude Reubi  
 Attorney Docket No.: 717816.23

has the general formula



wherein R<sub>3</sub> is a C<sub>1</sub>-C<sub>10</sub> alkylene group, a C<sub>1</sub>-C<sub>10</sub> alkylidene group or a C<sub>2</sub>-C<sub>10</sub> alkenylene group, and X is a thiocarbonyl group or a group of the general formula



wherein p is 1-5.

29. (Currently Amended): A labelled peptide of the general formula

H-(Xaa)<sub>n</sub>- (Xbb)<sub>m</sub>- Tyr - Xcc - Gly - Trp - Xdd - Asp - Phe - R<sub>2</sub> (I) (SEQ ID NO:27)

or an acid amide thereof, formed between a free NH<sub>2</sub>-group of an amino acid moiety and R<sub>1</sub>COOH, wherein

R<sub>1</sub> is a (C<sub>1</sub>-C<sub>3</sub>)alkanoyl group, an arylcarbonyl group, or an aryl-(C<sub>1</sub>-C<sub>3</sub>)alkanoyl group;  
or a lactam thereof, formed between a free NH<sub>2</sub> group of an amino acid moiety and a free CO<sub>2</sub>H  
group of another amino acid moiety;  
or a conjugate thereof with avidin or biotin;  
wherein:

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

(Xaa)<sub>n</sub> stands for 0 to 25 amino acid moieties which are equal or different and are selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg, Tyr, Trp, Val and Phe;

m = 0 or 1;

Xbb is Asp, Dpr, Glu or Pyr; with the proviso that Xbb can only be Pyr when n=0;

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and

R<sub>2</sub> is a hydroxy group, an acetoxy group or an amino group;

wherein one or more of the amino acids of said peptide can be in the D-configuration and wherein said peptide may comprise pseudo peptide bonds;

said peptide being labelled with (a) a radioactive metal isotope selected from the group consisting of <sup>99m</sup>Tc, <sup>203</sup>Pb, <sup>66</sup>Ga, <sup>67</sup>Ga, <sup>68</sup>Ga, <sup>72</sup>As, <sup>111</sup>In, <sup>113m</sup>In, <sup>114m</sup>In, <sup>97</sup>Ru, <sup>62</sup>Cu, <sup>64</sup>Cu, <sup>52</sup>Fe, <sup>52m</sup>Mn, <sup>51</sup>Cr, <sup>186</sup>Re, <sup>188</sup>Re, <sup>77</sup>As, <sup>90</sup>Y, <sup>67</sup>Cu, <sup>169</sup>Er, <sup>117m</sup>Sn, <sup>121</sup>Sn, <sup>127</sup>Te, <sup>142</sup>Pr, <sup>143</sup>Pr, <sup>198</sup>Au, <sup>199</sup>Au, <sup>149</sup>Tb, <sup>161</sup>Tb, <sup>109</sup>Pd, <sup>165</sup>Dy, <sup>149</sup>Pm, <sup>151</sup>Pm, <sup>153</sup>Sm, <sup>157</sup>Gd, <sup>159</sup>Gd, <sup>166</sup>Ho, <sup>172</sup>Tm, <sup>169</sup>Yb, <sup>175</sup>Yb, <sup>177</sup>Lu, <sup>105</sup>Rh and <sup>111</sup>Ag, or (b) with a paramagnetic metal atom selected from the group consisting of Cr, Mn, Fe, Co, Ni, Cu, Pr, Nd, Sm, Yb, Gd, Tb, Dy, Ho and Er, or (c) with a radioactive halogen isotope, selected from <sup>123</sup>I, <sup>124</sup>I, <sup>125</sup>I, <sup>131</sup>I, <sup>75</sup>Br, <sup>76</sup>Br, <sup>77</sup>Br and <sup>82</sup>Br, wherein The labelled peptide of claim 26 wherein said peptide comprises DTPA and is selected from the group consisting of DTPA-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:19), DTPA-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:20), DTPA-DAsp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:21), DTPA-DAsp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:22) and Dpr(β-DTPA)-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:23).



Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

30. (Currently Amended): A labelled peptide of the general formula

H-(Xaa)<sub>n</sub>- (Xbb)<sub>m</sub>- Tyr - Xcc - Gly - Trp - Xdd - Asp - Phe - R<sub>2</sub> (I) (SEQ ID NO:27)

or an acid amide thereof, formed between a free NH<sub>2</sub>-group of an amino acid moiety and

R<sub>1</sub>COOH, wherein

R<sub>1</sub> is a (C<sub>1</sub>-C<sub>3</sub>)alkanoyl group, an arylcarbonyl group, or an aryl-(C<sub>1</sub>-C<sub>3</sub>)alkanoyl group;  
or a lactam thereof, formed between a free NH<sub>2</sub> group of an amino acid moiety and a free CO<sub>2</sub>H  
group of another amino acid moiety;

or a conjugate thereof with avidin or biotin;

wherein:

(Xaa)<sub>n</sub> stands for 0 to 25 amino acid moieties which are equal or different and are  
selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg,  
Tyr, Trp, Val and Phe;

m = 0 or 1;

Xbb is Asp, Dpr, Glu or Pyr; with the proviso that Xbb can only be Pyr when n =0;

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and

R<sub>2</sub> is a hydroxy group, an acetoxy group or an amino group;

wherein one or more of the amino acids of said peptide can be in the D-configuration and  
wherein said peptide may comprise pseudo peptide bonds;

said peptide being labelled with (a) a radioactive metal isotope selected from the group

consisting of <sup>99m</sup>Tc, <sup>203</sup>Pb, <sup>66</sup>Ga, <sup>67</sup>Ga, <sup>68</sup>Ga, <sup>72</sup>As, <sup>111</sup>In, <sup>113m</sup>In, <sup>114m</sup>In, <sup>97</sup>Ru, <sup>62</sup>Cu, <sup>64</sup>Cu, <sup>52</sup>Fe,

<sup>52m</sup>Mn, <sup>51</sup>Cr, <sup>186</sup>Re, <sup>188</sup>Re, <sup>77</sup>As, <sup>90</sup>Y, <sup>67</sup>Cu, <sup>169</sup>Er, <sup>117m</sup>Sn, <sup>121</sup>Sn, <sup>127</sup>Te, <sup>142</sup>Pr, <sup>143</sup>Pr, <sup>198</sup>Au, <sup>199</sup>Au,

<sup>149</sup>Tb, <sup>161</sup>Tb, <sup>109</sup>Pd, <sup>165</sup>Dy, <sup>149</sup>Pm, <sup>151</sup>Pm, <sup>153</sup>Sm, <sup>157</sup>Gd, <sup>159</sup>Gd, <sup>166</sup>Ho, <sup>172</sup>Tm, <sup>169</sup>Yb, <sup>175</sup>Yb, <sup>177</sup>Lu,

<sup>105</sup>Rh and <sup>111</sup>Ag, or (b) with a paramagnetic metal atom selected from the group consisting of Cr,

Mn, Fe, Co, Ni, Cu, Pr, Nd, Sm, Yb, Gd, Tb, Dy, Ho and Er, or (c) with a radioactive halogen

isotope, selected from <sup>123</sup>I, <sup>124</sup>I, <sup>125</sup>I, <sup>131</sup>I, <sup>75</sup>Br, <sup>76</sup>Br, <sup>77</sup>Br and <sup>82</sup>Br, wherein The labelled peptide

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

of claim 26 wherein said peptide comprises DTPA and is selected from the group consisting of DTPA-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:20) and DTPA-DAsp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:21).

31. (Previously Presented): A method for preparing a labelled peptide of general formula H - (Xaa)<sub>n</sub> - (Xbb)<sub>m</sub> - Tyr - Xcc - Gly - Trp - Xdd - Asp- Phe - R<sub>2</sub> (I) (SEQ ID NO:27) or an acid amide thereof, formed between a free NH<sub>2</sub>-group of an amino acid moiety and R<sub>1</sub>COOH, wherein

R<sub>1</sub> is a (C<sub>1</sub>-C<sub>3</sub>)alkanoyl group, an arylcarbonyl group, or an aryl-(C<sub>1</sub>-C<sub>3</sub>)alkanoyl group; or a lactam thereof, formed between a free NH<sub>2</sub> group of an amino acid moiety and a free CO<sub>2</sub>H group of another amino acid moiety; or a conjugate thereof with avidin or biotin; wherein:

(Xaa)<sub>n</sub> stands for 0 to 25 amino acid moieties which are equal or different and are selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg, Tyr, Trp, Val and Phe;

m = 0 or 1;

Xbb is Asp, Dpr, Glu or Pyr; with the proviso that Xbb can only be Pyr when n = 0;

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and

R<sub>2</sub> is a hydroxy group, an acetoxy group or an amino group;

wherein one or more of the amino acids of said peptide can be in the D-configuration and wherein said peptide may comprise pseudo peptide bonds;

said peptide being labelled with (a) a radioactive metal isotope selected from the group consisting of <sup>99m</sup>Tc, <sup>203</sup>Pb, <sup>66</sup>Ga, <sup>67</sup>Ga, <sup>68</sup>Ga, <sup>72</sup>As, <sup>111</sup>In, <sup>113m</sup>In, <sup>114m</sup>In, <sup>97</sup>Ru, <sup>62</sup>Cu, <sup>64</sup>Cu, <sup>52</sup>Fe, <sup>52m</sup>Mn, <sup>51</sup>Cr, <sup>186</sup>Re, <sup>188</sup>Re, <sup>77</sup>As, <sup>90</sup>Y, <sup>67</sup>Cu, <sup>169</sup>Er, <sup>117m</sup>Sn, <sup>121</sup>Sn, <sup>127</sup>Te, <sup>142</sup>Pr, <sup>143</sup>Pr, <sup>198</sup>Au, <sup>199</sup>Au, <sup>149</sup>Tb, <sup>161</sup>Tb, <sup>109</sup>Pd, <sup>165</sup>Dy, <sup>149</sup>Pm, <sup>151</sup>Pm, <sup>153</sup>Sm, <sup>157</sup>Gd, <sup>159</sup>Gd, <sup>166</sup>Ho, <sup>172</sup>Tm, <sup>169</sup>Yb, <sup>175</sup>Yb, <sup>177</sup>Lu,

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

$^{105}\text{Rh}$  and  $^{111}\text{Ag}$ , or (b) with a paramagnetic metal atom selected from the group consisting of Cr, Mn, Fe, Co, Ni, Cu, Pr, Nd, Sm, Yb, Gd, Tb, Dy, Ho and Er, or (c) with a radioactive halogen isotope, selected from  $^{123}\text{I}$ ,  $^{124}\text{I}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{75}\text{Br}$ ,  $^{76}\text{Br}$ ,  $^{77}\text{Br}$  and  $^{82}\text{Br}$ ;

wherein said peptide comprises a chelating group bound by an amide bond or through a spacing group to said peptide;

said method comprising reacting said peptide with said metal isotope or said metal atom in the form of a salt or of a chelate, bound to a comparatively weak chelator, to form a complex.

32. (Previously Presented): A kit for preparing a radiopharmaceutical composition, comprising (i) a derivatized peptide of general formula

$\text{H} - (\text{Xaa})_n - (\text{Xbb})_m - \text{Tyr} - \text{Xcc} - \text{Gly} - \text{Trp} - \text{Xdd} - \text{Asp} - \text{Phe} - \text{R}_2$  (I) (SEQ ID NO:27)

or an acid amide thereof, formed between a free  $\text{NH}_2$ -group of an amino acid moiety and  $\text{R}_1\text{COOH}$ , wherein

$\text{R}_1$  is a  $(\text{C}_1\text{-C}_3)$ alkanoyl group, an arylcarbonyl group, or an aryl- $(\text{C}_1\text{-C}_3)$ alkanoyl group; or a lactam thereof, formed between a free  $\text{NH}_2$  group of an amino acid moiety and a free  $\text{CO}_2\text{H}$  group of another amino acid moiety; or a conjugate thereof with avidin or biotin; wherein:

$(\text{Xaa})_n$  stands for 0 to 25 amino acid moieties which are equal or different and are selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg, Tyr, Trp, Val and Phe;

$m = 0$  or  $1$ ;

Xbb is Asp, Dpr, Glu or Pyr; with the proviso that Xbb can only be Pyr when  $n = 0$ ;

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and

$\text{R}_2$  is a hydroxy group, an acetoxy group or an amino group;

wherein one or more of the amino acids of said peptide can be in the D-configuration and

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

wherein said peptide may comprise pseudo peptide bonds;  
to which derivatized peptide, if desired, an inert pharmaceutically acceptable carrier and/or formulating agents and/or adjuvants is/are added, (ii) a solution of a salt or chelate of a metal selected from the group consisting of the radioactive isotopes  $^{99m}\text{Tc}$ ,  $^{203}\text{Pb}$ ,  $^{66}\text{Ga}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{72}\text{As}$ ,  $^{111}\text{In}$ ,  $^{113m}\text{In}$ ,  $^{114m}\text{In}$ ,  $^{97}\text{Ru}$ ,  $^{62}\text{Cu}$ ,  $^{64}\text{Cu}$ ,  $^{52}\text{Fe}$ ,  $^{52m}\text{Mn}$ ,  $^{51}\text{Cr}$ ,  $^{186}\text{Re}$ ,  $^{188}\text{Re}$ ,  $^{77}\text{As}$ ,  $^{90}\text{Y}$ ,  $^{67}\text{Cu}$ ,  $^{169}\text{Er}$ ,  $^{117m}\text{Sn}$ ,  $^{121}\text{Sn}$ ,  $^{127}\text{Te}$ ,  $^{142}\text{Pr}$ ,  $^{143}\text{Pr}$ ,  $^{198}\text{Au}$ ,  $^{199}\text{Au}$ ,  $^{149}\text{Tb}$ ,  $^{161}\text{Tb}$ ,  $^{109}\text{Pd}$ ,  $^{165}\text{Dy}$ ,  $^{149}\text{Pm}$ ,  $^{151}\text{Pm}$ ,  $^{153}\text{Sm}$ ,  $^{157}\text{Gd}$ ,  $^{159}\text{Gd}$ ,  $^{166}\text{Ho}$ ,  $^{172}\text{Tm}$ ,  $^{169}\text{Yb}$ ,  $^{175}\text{Yb}$ ,  $^{177}\text{Lu}$ ,  $^{105}\text{Rh}$  and  $^{111}\text{Ag}$ , and (iii) instructions for use with a prescription for reacting the ingredients present in the kit.

33. (Previously Presented): A kit for preparing a radiopharmaceutical composition, comprising (i) a derivatized peptide of general formula:

$\text{H} - (\text{Xaa})_n - (\text{Xbb})_m - \text{Tyr} - \text{Xcc} - \text{Gly} - \text{Trp} - \text{Xdd} - \text{Asp} - \text{Phe} - \text{R}_2$  (I) (SEQ ID NO:27)  
or an acid amide thereof, formed between a free  $\text{NH}_2$ -group of an amino acid moiety and  $\text{R}_1\text{COOH}$ , wherein

$\text{R}_1$  is a  $(\text{C}_1\text{-C}_3)$ alkanoyl group, an arylcarbonyl group, or an aryl- $(\text{C}_1\text{-C}_3)$ alkanoyl group; or a lactam thereof, formed between a free  $\text{NH}_2$  group of an amino acid moiety and a free  $\text{CO}_2\text{H}$  group of another amino acid moiety;  
or a conjugate thereof with avidin or biotin; wherein:

$(\text{Xaa})_n$  stands for 0 to 25 amino acid moieties which are equal or different and are selected from Ala, Leu, Asn, Dpr, Gln, Glu, Ser, Ile, Met, His, Asp, Lys, Gly, Thr, Pro, Pyr, Arg, Tyr, Trp, Val and Phe;

$m = 0$  or  $1$ ;

Xbb is Asp, Dpr, Glu or Pyr; with the proviso that Xbb can only be Pyr when  $n = 0$ ;

Xcc is Met, Leu or Nle;

Xdd is Met, Leu or Nle; and

$\text{R}_2$  is a hydroxy group, an acetoxy group or an amino group;

wherein one or more of the amino acids of said peptide can be in the D-configuration and wherein said peptide may comprise pseudo peptide bonds;

Application Serial No. 10/626,229  
Third Preliminary Amendment  
Inventor(s) Name: Jean-Claude Reubi  
Attorney Docket No.: 717816.23

to which derivatized peptide, if desired, an inert pharmaceutically acceptable carrier and/or formulating agents and/or adjuvants is/are added, (ii) a reducing agent, and, if desired, a chelator, said ingredients (i) and (ii) optionally being combined, and (iii) instructions for use with a prescription for reacting the ingredients of the kit with  $^{99m}\text{Tc}$  in the form of a pertechnetate solution or with  $^{186}\text{Re}$  or  $^{188}\text{Re}$  in the form of a perrhenate solution.

34. (Previously Presented): The method of claim 1, 2, or 3, wherein said peptide is selected from the group consisting of H-Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:3) and H-DAsp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-NH<sub>2</sub> (SEQ ID NO:4).

35. (Currently Amended): The method of ~~claim 2 wherein~~ claim 2, wherein said peptide is labelled with a radioactive halogen isotope selected from the group consisting of  $^{123}\text{I}$  and  $^{125}\text{I}$ , said radioactive halogen isotope being attached to a Tyr or Trp moiety of the peptide, or to the aryl group of substituent R<sub>1</sub>.

36. (Currently Amended): The method of ~~claim 3 wherein~~ claim 3, wherein said peptide is labelled with a radioactive halogen isotope selected from the group consisting of  $^{125}\text{I}$ ,  $^{131}\text{I}$  and  $^{82}\text{Br}$ , said radioactive halogen isotope being attached to a Tyr or Trp moiety of the peptide, or to the aryl group of substituent R<sub>1</sub>.